Maria JoÃ£o Saraiva

List of Publications by Year
in descending order

222 papers	11,151 citations	22153 59 h-index	39675 94 g-index
225 all docs	225 docs citations	225 times ranked	7503 citing authors

#	Article	IF	Citations
1	Amyloid: Toward terminology clarification Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 1-4.	3.0	314
2	A primer of amyloid nomenclature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 179-183.	3.0	306
3	Deposition of Transthyretin in Early Stages of Familial Amyloidotic Polyneuropathy. American Journal of Pathology, 2001, 159, 1993-2000.	3.8	303
4	Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2010, 17, 101-104.	3.0	302
5	Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin Variants. Journal of Biological Chemistry, 2001, 276, 27207-27213.	3.4	274
6	Transthyretin mutations in health and disease. Human Mutation, 1995, 5, 191-196.	2.5	239
7	Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 167-170.	3.0	229
8	Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Human Mutation, 2001, 17, 493-503.	2.5	200
9	Familial Amyloid Polyneuropathy: Receptor for Advanced Glycation End Products-Dependent Triggering of Neuronal Inflammatory and Apoptotic Pathways. Journal of Neuroscience, 2001, 21, 7576-7586.	3.6	190
10	Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 34-36.	3.0	184
11	Amyloid Fibril Protein Nomenclature - 2002. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 197-200.	3.0	176
12	The Tetrameric Protein Transthyretin Dissociates to a Non-native Monomer in Solution. Journal of Biological Chemistry, 1999, 274, 32943-32949.	3.4	160
13	Interaction of the Receptor for Advanced Glycation End Products (RAGE) with Transthyretin Triggers Nuclear Transcription Factor kB (NF-kB) Activation. Laboratory Investigation, 2000, 80, 1101-1110.	3.7	156
14	Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. Journal of Translational Medicine, 2010, 8, 74.	4.4	149
15	Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB Journal, 2006, 20, 234-239.	0.5	136
16	Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters, 2011, 585, 2424-2430.	2.8	133
17	Transthyretin: a multifaceted protein. Biomolecular Concepts, 2014, 5, 45-54.	2.2	128
18	Transthyretin binding to Aâ€Beta peptide â€“ Impact on Aâ€Beta fibrillogenesis and toxicity. FEBS Letters, 2008, 582, 936-942.	2.8	125

#	Article	IF	Citations
19	Accelerated AÂ Deposition in APPswe/PS1ÂE9 Mice with Hemizygous Deletions of TTR (Transthyretin). Journal of Neuroscience, 2007, 27, 7006-7010.	3.6	124
20	Binding of epigallocatechinâ€3â€gallate to transthyretin modulates its amyloidogenicity. FEBS Letters, 2009, 583, 3569-3576.	2.8	122
21	Transthyretin enhances nerve regeneration. Journal of Neurochemistry, 2007, 103, 831-839.	3.9	118
22	Transthyretin Internalization by Sensory Neurons Is Megalin Mediated and Necessary for Its Neuritogenic Activity. Journal of Neuroscience, 2009, 29, 3220-3232.	3.6	118
23	4 â€²â€iodoâ€4â€²â€Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB Journal, 2003, 17, 803-809.	0.5	117
24	The Crystal Structure of Amyloidogenic Leu55â†' Pro Transthyretin Variant Reveals a Possible Pathway for Transthyretin Polymerization into Amyloid Fibrils. Journal of Biological Chemistry, 1998, 273, 24715-24722.	3.4	116
25	Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Progress in Neurobiology, 2003, 71, 385-400.	5.7	116
26	Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils 1 1Edited by M. Moody. Journal of Molecular Biology, 2002, 317, 683-695.	4.2	112
27	Transthyretin is involved in depression-like behaviour and exploratory activity. Journal of Neurochemistry, 2004, 88, 1052-1058.	3.9	111
28	Evidence for the Role of Megalin in Renal Uptake of Transthyretin. Journal of Biological Chemistry, 2000, 275, 38176-38181.	3.4	109
29	Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Human Molecular Genetics, 2005, 14, 543-553.	2.9	108
30	Evidence for Early Cytotoxic Aggregates in Transgenic Mice for Human Transthyretin Leu55Pro. American Journal of Pathology, 2002, 161, 1935-1948.	3.8	98
31	Transthyretin and Alzheimer's disease: Where in the brain?. Neurobiology of Aging, 2007, 28, 713-718.	3.1	97
32	Transthyretin Protects against A-Beta Peptide Toxicity by Proteolytic Cleavage of the Peptide: A Mechanism Sensitive to the Kunitz Protease Inhibitor. PLoS ONE, 2008, 3, e2899.	2.5	95
33	The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Letters, 1997, 418, 297-300.	2.8	94
34	Apolipoprotein AI and Transthyretin as Components of Amyloid Fibrils in a Kindred with apoAI Leu178His Amyloidosis. American Journal of Pathology, 2000, 156, 1911-1917.	3.8	94
35	Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: â€œIn Vivoâ€• Evidence from FAP Mice Models. PLoS ONE, 2012, 7, e29933.	2.5	94
36	BDNF gene delivery mediated by neuron-targeted nanoparticles is neuroprotective in peripheral nerve injury. Biomaterials, 2017, 121, 83-96.	11.4	92

#	Article	IF	Citations
37	Thyroxine binding to transthyretin Met 119. Endocrine, 1997, 6, 309-315.	2.3	90
38	Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 109-118.	3.0	89
39	Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 2004, 381, 351-356.	3.7	88
40	Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP). Biochemistry, 1991, 30, 2415-2421.	2.5	86
41	Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. Journal of Molecular Biology, 2001, 306, 733-744.	4.2	85
42	Transthyretin amyloidosis: a tale of weak interactions. FEBS Letters, 2001, 498, 201-203.	2.8	82
43	Review: TTR Amyloidosisâ€"Structural Features Leading to Protein Aggregation and Their Implications on Therapeutic Strategies. Journal of Structural Biology, 2000, 130, 290-299.	2.8	78
44	Haplotype analysis of familial amyloidotic polyneuropathy. Human Genetics, 1989, 82, 9-13.	3.8	77
45	Transthyretin, a New Cryptic Protease. Journal of Biological Chemistry, 2004, 279, 21431-21438.	3.4	76
46	Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5584-5589.	7.1	76
47	Endoplasmic Reticulum Stress Associated with Extracellular Aggregates. Journal of Biological Chemistry, 2006, 281, 21998-22003.	3.4	75
48	Transthyretin in high density lipoproteins: association with apolipoprotein A-I. Journal of Lipid Research, 2000, 41, 58-65.	4.2	75
49	CSF transthyretin neuroprotection in a mouse model of brain ischemia. Journal of Neurochemistry, 2010, 115, 1434-1444.	3.9	73
50	Transthyretin participates in beta-amyloid transport from the brain to the liver- involvement of the low-density lipoprotein receptor-related protein 1?. Scientific Reports, 2016, 6, 20164.	3.3	71
51	Comparative Stability and Clearance of [Met30]Transthyretin and [Met119]Transthyretin. FEBS Journal, 1997, 249, 662-668.	0.2	68
52	Ultrastructure of Familial Amyloid Polyneuropathy Amyloid Fibrils: Examination with High-Resolution Electron Microscopy. Journal of Structural Biology, 1998, 124, 1-12.	2.8	67
53	Upâ€regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinaseâ€associated lipocalin and matrix metalloproteinaseâ€9 in familial amyloid polyneuropathy. FASEB Journal, 2005, 19, 124-126.	0.5	67
54	Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3108-3113.	7.1	65

#	Article	IF	Citations
55	Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Laboratory Investigation, 2004, 84, 865-873.	3.7	64
56	ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. Journal of Lipid Research, 2007, 48, 2385-2395.	4.2	64
57	Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB Journal, 2006, 20, 166-168.	0.5	62
58	Comparative Studies of Two Transthyretin Variants with Protective Effects on Familial Amyloidotic Polyneuropathy: TTR R104H and TTR T119M. Biochemical and Biophysical Research Communications, 2000, 270, 1024-1028.	2.1	61
59	Internalization of Transthyretin. Journal of Biological Chemistry, 2001, 276, 14420-14425.	3.4	61
60	Enlarged ventricles, astrogliosis and neurodegeneration in heat shock factor 1 null mouse brain. Neuroscience, 2004, 126, 657-663.	2.3	61
61	The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiology of Aging, 2010, 31, 280-289.	3.1	59
62	Transthyretin is up-regulated by sex hormones in mice liver. Molecular and Cellular Biochemistry, 2008, 317, 137-142.	3.1	57
63	Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 517-522.	3.8	57
64	A Novel Compound Heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with High Serum Transthyretin (TTR) and Retinol Binding Protein (RBP) Levels. Biochemical and Biophysical Research Communications, 1999, 264, 365-370.	2.1	55
65	4â€²-Iodo-4â€²-Deoxydoxorubicin Disrupts the Fibrillar Structure of Transthyretin Amyloid. American Journal of Pathology, 2000, 156, 1919-1925.	3.8	55
66	Gd-nanoparticles functionalization with specific peptides for ÃŸ-amyloid plaques targeting. Journal of Nanobiotechnology, 2016, 14, 60.	9.1	55
67	Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses. CNS and Neurological Disorders, 2005, 4, 587-596.	4.3	54
68	Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophysical Chemistry, 2000, 88, 61-67.	2.8	53
69	Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. Biochemical Journal, 2005, 388, 615-621.	3.7	53
70	Activation of ERK1/2 MAP kinases in Familial Amyloidotic Polyneuropathy. Journal of Neurochemistry, 2006, 97, 151-161.	3.9	52
71	Transthyretin Deposition in Familial Amyloidotic Polyneuropathy. Current Medicinal Chemistry, 2012, 19, 2304-2311.	2.4	52
72	Thyroid hormone distribution in the mouse brain: the role of transthyretin. Neuroscience, 2002, 113, 837-847.	2.3	51

#	Article	IF	Citations
73	Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotypeâ€“phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden. European Journal of Human Genetics, 2004, 12, 225-237.	2.8	51
74	Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis Inhibitors. PLoS ONE, 2009, 4, e4124.	2.5	51
75	Family Studies of the Genetic Abnormality in Transthyretin (Prealbumin) in Portuguese Patients with Familial Amyloidotic Poly neuropathy. Annals of the New York Academy of Sciences, 1984, 435, 86-100.	3.8	50
76	Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation. Current Alzheimer Research, 2012, 9, 881-889.	1.4	48
77	Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: Ocular synthesis of mutant transthyretin. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 266-269.	3.0	46
78	Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. Journal of Molecular Biology, 2000, 304, 461-470.	4.2	45
79	The Crystal Structure of Transthyretin in Complex with Diethylstilbestrol. Journal of Biological Chemistry, 2004, 279, 53483-53490.	3.4	45
80	Design and biological activity of Î²-sheet breaker peptide conjugates. Biochemical and Biophysical Research Communications, 2009, 380, 397-401.	2.1	45
81	Transthyretin Stabilization by Iododiflunisal Promotes Amyloid-Î² Peptide Clearance, Decreases its Deposition, and Ameliorates Cognitive Deficits in an Alzheimer's Disease Mouse Model. Journal of Alzheimer's Disease, 2014, 39, 357-370.	2.6	45
82	Analysis of x-ray diffraction patterns from amyloid of biopsied vitreous humor and kidney of transthyretin (TTR) Met30 familial amyloidotic polyneuropathy (FAP) patients: axially arrayed TTR monomers constitute the protofilament. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 163-174.	3.0	44
83	Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Reviews in Molecular Medicine, 2002, 4, 1-11.	3.9	44
84	Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5270-5273.	2.2	44
85	Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Laboratory Investigation, 2006, 86, 23-31.	3.7	43
86	Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 39-45.	3.8	43
87	The molecular interaction of 4â€²-iodo-4â€²-deoxydoxorubicin with Leu-55Pro transthyretin â€˜amyloid-likeâ€™ oligomer leading to disaggregation. Biochemical Journal, 2000, 351, 273-279.	3.7	42
88	Controlling Amyloidâ€Î² Peptide(1â€“42) Oligomerization and Toxicity by Fluorinated Nanoparticles. ChemBioChem, 2010, 11, 1905-1913.	2.6	42
89	Distinct Annular Oligomers Captured along the Assembly and Disassembly Pathways of Transthyretin Amyloid Protofibrils. PLoS ONE, 2012, 7, e44992.	2.5	42
90	A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nature Communications, 2021, 12, 3142.	12.8	42

#	Article	IF	Citations
91	Screening and biochemical characterization of transthyretin variants in the Portuguese population. Human Mutation, 1997, 9, 226-233.	2.5	41
92	17Î²-Estradiol Induces Transthyretin Expression in Murine Choroid Plexus via an Oestrogen Receptor Dependent Pathway. Cellular and Molecular Neurobiology, 2009, 29, 475-483.	3.3	41
93	Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics, 2014, 11, 450-461.	4.4	41
94	Gender-Dependent Transthyretin Modulation of Brain Amyloid-Î² Levels: Evidence from a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 429-439.	2.6	40
95	Transthyretin is a metallopeptidase with an inducible active site. Biochemical Journal, 2012, 443, 769-778.	3.7	40
96	Transthyretin Leu 68 in a form of cardiac amyloidosis. Basic Research in Cardiology, 1991, 86, 567-571.	5.9	39
97	â€˜In vitroâ€™ amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1316, 35-42.	3.8	39
98	Sporadic Cases of Hereditary Systemic Amyloidosis. New England Journal of Medicine, 2002, 346, 1818-1819.	27.0	39
99	Kinetic Assay for High-Throughput Screening of In Vitro Transthyretin Amyloid Fibrillogenesis Inhibitors. ACS Combinatorial Science, 2005, 7, 246-252.	3.3	39
100	Stability of the Transthyretin Molecule as a Key Factor in the Interaction with A-Beta Peptide - Relevance in Alzheimer's Disease. PLoS ONE, 2012, 7, e45368.	2.5	39
101	Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 175-184.	3.0	38
102	Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis. Scientific Reports, 2016, 6, 26623.	3.3	38
103	Onset in the seventh decade and lack of symptoms in heterozygotes for the TTRMet30 mutation in hereditary amyloid neuropathyâ€”type I (Portuguese, Andrade). American Journal of Medical Genetics Part A, 1987, 27, 345-357.	2.4	37
104	Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis, 2007, 28, 2053-2064.	2.4	37
105	Randomization of Amyloidâ€Î²â€Peptide(1â€42) Conformation by Sulfonated and Sulfated Nanoparticles Reduces Aggregation and Cytotoxicity. Macromolecular Bioscience, 2010, 10, 1152-1163.	4.1	35
106	Transthyretin Interacts with Metallothionein 2. Biochemistry, 2008, 47, 2244-2251.	2.5	34
107	Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacological Research, 2010, 62, 514-522.	7.1	34
108	Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family: Clinical and neurophysiological studies. Muscle and Nerve, 2003, 28, 715-721.	2.2	32

#	Article	IF	Citations
109	Solution Structure of the Soluble Receptor for Advanced Glycation End Products (sRAGE). Journal of Biological Chemistry, 2011, 286, 37525-37534.	3.4	32
110	Structure of the Val122Ile Variant Transthyretin â€“ a Cardiomyopathic Mutant. Acta Crystallographica Section D: Biological Crystallography, 1996, 52, 966-972.	2.5	31
111	Genetic anticipation in Portuguese kindreds with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions. Human Genetics, 1999, 104, 480-485.	3.8	31
112	Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 54-61.	3.0	31
113	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 97-102.	3.0	31
114	The binding of xanthone derivatives to transthyretin. Biochemical Pharmacology, 2005, 70, 1861-1869.	4.4	30
115	Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochemical Journal, 2007, 408, 131-138.	3.7	30
116	Transthyretin gene in Alzheimer's disease patients. Neuroscience Letters, 1996, 204, 212-214.	2.1	29
117	Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting. Nanomedicine, 2017, 12, 1675-1687.	3.3	29
118	Recent advances in the molecular pathology of familial amyloid polyneuropathy. Neuromuscular Disorders, 1991, 1, 3-6.	0.6	28
119	Preimplantation genetic diagnosis for familial amyloidotic polyneuropathy (FAP). Prenatal Diagnosis, 2001, 21, 1093-1099.	2.3	28
120	5Î±-dihydrotestosterone up-regulates transthyretin levels in mice and rat choroid plexus via an androgen receptor independent pathway. Brain Research, 2008, 1229, 18-26.	2.2	28
121	Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. International Journal of Molecular Sciences, 2019, 20, 1287.	4.1	28
122	Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease. Journal of Controlled Release, 2015, 198, 80-90.	9.9	27
123	Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin. Neurogenetics, 2004, 5, 61-67.	1.4	26
124	Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 39-42.	3.0	26
125	Human metallothioneins 2 and 3 differentially affect amyloidâ€beta binding by transthyretin. FEBS Journal, 2010, 277, 3427-3436.	4.7	25
126	Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin. FEBS Letters, 2012, 586, 2891-2896.	2.8	25

#	Article	IF	Citations
127	Transthyretin Induces Insulin-like Growth Factor I Nuclear Translocation Regulating Its Levels in the Hippocampus. Molecular Neurobiology, 2015, 51, 1468-1479.	4.0	25
128	The molecular interaction of 4â€²-iodo-4â€²-deoxydoxorubicin with Leu-55Pro transthyretin â€˜amyloid-likeâ€™ oligomer leading to disaggregation. Biochemical Journal, 2000, 351, 273.	3.7	24
129	In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Letters, 2006, 580, 3451-3456.	2.8	24
130	Biomarkers in the Assessment of Therapies for Familial Amyloidotic Polyneuropathy. Molecular Medicine, 2007, 13, 584-591.	4.4	24
131	Structural basis for the protective role of sulfite against transthyretin amyloid formation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 59-64.	2.3	24
132	Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis. Laboratory Investigation, 2013, 93, 911-920.	3.7	24
133	The inflammatory response to sciatic nerve injury in a familial amyloidotic polyneuropathy mouse model. Experimental Neurology, 2014, 257, 76-87.	4.1	24
134	Modulation of the Mechanisms Driving Transthyretin Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 592644.	2.9	24
135	Transthyretin Regulates Thyroid Hormone Levels in the Choroid Plexus, But Not in the Brain Parenchyma: Study in a Transthyretin-Null Mouse Model. Endocrinology, 2000, 141, 3267-3272.	2.8	24
136	Structure and assemblyâ€“disassembly properties of wildâ€type transthyretin amyloid protofibrils observed with atomic force microscopy. Journal of Molecular Recognition, 2011, 24, 467-476.	2.1	22
137	Delivery of an antiâ€transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons. Journal of Neurochemistry, 2018, 145, 393-408.	3.9	22
138	Haplotype analysis of common transthyretin mutations. Human Genetics, 1995, 96, 350-4.	3.8	21
139	Transthyretin is not necessary for thyroid hormone metabolism in conditions of increased hormone demand. Journal of Endocrinology, 2005, 187, 257-266.	2.6	21
140	Extracellular Matrix Markers for Disease Progression and Follow-Up of Therapies in Familial Amyloid Polyneuropathy V30M TTR-Related. Disease Markers, 2008, 25, 37-47.	1.3	21
141	Aprotinin binding to amyloid fibrils. FEBS Journal, 2000, 267, 2307-2311.	0.2	20
142	Mutant fibrinogen A-Î±-chain associated with hereditary renal amyloidosis and peripheral neuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11, 200-207.	3.0	20
143	Clusterin Overexpression and Its Possible Protective Role in Transthyretin Deposition in Familial Amyloidotic Polyneuropathy. Journal of Neuropathology and Experimental Neurology, 2011, 70, 1097-1106.	1.7	20
144	Progesterone Enhances Transthyretin Expression in the Rat Choroid Plexus In Vitro and In Vivo via Progesterone Receptor. Journal of Molecular Neuroscience, 2011, 44, 152-158.	2.3	19

#	Article	IF	Citations
145	TTR exon scanning in peripheral neuropathies. Neuromuscular Disorders, 1995, 5, 187-191.	0.6	18
146	New transthyretin mutation V28M in a Portuguese kindred with amyloid polyneuropathy. Muscle and Nerve, 2000, 23, 1016-1021.	2.2	18
147	Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy. Journal of Molecular Medicine, 2001, 78, 703-707.	3.9	18
148	X-ray Absorption Spectroscopy Reveals a Substantial Increase of Sulfur Oxidation in Transthyretin (TTR) upon Fibrillization. Journal of Biological Chemistry, 2003, 278, 11654-11660.	3.4	18
149	MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy. DMM Disease Models and Mechanisms, 2017, 10, 1253-1260.	2.4	18
150	Tetramer formation of a variant type human transthyretin (prealbumin) produced byEscherichia coli expression system. Biochemical and Biophysical Research Communications, 1989, 163, 851-859.	2.1	17
151	Thyroxine binding to transthyretin (TTR) variantsâ€"two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity. European Journal of Endocrinology, 1996, 135, 226-230.	3.7	17
152	Transthyretin regulates hippocampal 14â€3â€3Î¶ protein levels. FEBS Letters, 2013, 587, 1482-1488.	2.8	17
153	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition. European Journal of Medicinal Chemistry, 2016, 121, 823-840.	5.5	17
154	Transthyretin ALA 71: A new transthyretin variant in a Spanish family with familial amyloidotic polyneuropathy. Human Mutation, 1993, 2, 420-421.	2.5	16
155	Impairment of the ubiquitinâ€"proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. Journal of Pathology, 2007, 213, 200-209.	4.5	16
156	Iodination of salicylic acid improves its binding to transthyretin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 512-517.	2.3	16
157	A novel nanoparticle delivery system for in vivo targeting of the sciatic nerve: impact on regeneration. Nanomedicine, 2012, 7, 1167-1180.	3.3	16
158	Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Scientific Reports, 2017, 7, 44709.	3.3	16
159	Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system. Journal of Neuroinflammation, 2017, 14, 115.	7.2	16
160	Transthyretin is not expressed by dorsal root ganglia cells. Experimental Neurology, 2008, 214, 362-365.	4.1	15
161	Structural insights into a zinc-dependent pathway leading to Leu55Pro transthyretin amyloid fibrils. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 1035-1044.	2.5	15
162	Presence of Nâ€glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from <scp>ERAD</scp>. Journal of Cellular and Molecular Medicine, 2013, 17, 429-435.	3.6	15

#	Article	IF	Citations
163	Ocular changes in familial amyloidotic polyneuropathy with dense vitreous opacities. Eye, 1991, 5, 99-105.	2.1	14
164	Unusual Self-Association Properties of Transthyretin Y114C Related to Familial Amyloidotic Polyneuropathy: Effects on Detection and Quantification. Biochemical and Biophysical Research Communications, 1999, 261, 264-269.	2.1	14
165	Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity. Biochemical Journal, 2000, 348, 167.	3.7	14
166	Familial Amyloidotic Polyneuropathy: Protein Aggregation in the Peripheral Nervous System. Journal of Molecular Neuroscience, 2004, 23, 035-040.	2.3	14
167	The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 512-519.	2.5	14
168	Structural studies on FAP fibrils: removal of contaminants is essential for the interpretation of X-ray data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 173-178.	3.0	13
169	Activation of the Heat Shock Response in Familial Amyloidotic Polyneuropathy. Journal of Neuropathology and Experimental Neurology, 2008, 67, 449-455.	1.7	13
170	Î±Bâ€crystallin (HspB5) in familial amyloidotic polyneuropathy. International Journal of Experimental Pathology, 2010, 91, 515-521.	1.3	13
171	Familial amyloidotic polyneuropathy: transthyretin (prealbumin) variants in kindreds of Italian origin. Human Genetics, 1988, 80, 341-343.	3.8	12
172	Studies on the synthesis and secretion of transthyretin by the human hepatoma cell line Hep G2. FEBS Letters, 1991, 287, 193-196.	2.8	12
173	X-ray crystallographic studies of two transthyretin variants: further insights into amyloidogenesis. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 333-339.	2.5	12
174	Glial cells in familial amyloidotic polyneuropathy. Acta Neuropathologica Communications, 2014, 2, 177.	5.2	12
175	C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy. PLoS ONE, 2017, 12, e0175767.	2.5	12
176	Two Spanish sibs with familial amyloidotic polyneuropathy homozygous for the V30M-TTR gene. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2001, 8, 121-123.	3.0	11
177	Transthyretin: roles in the nervous system beyond thyroxine and retinol transport. Expert Review of Endocrinology and Metabolism, 2012, 7, 181-189.	2.4	11
178	Impairment of autophagy by TTR V30M aggregates: inÂvivo reversal by TUDCA and curcumin. Clinical Science, 2016, 130, 1665-1675.	4.3	11
179	Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1183-1193.	3.8	10
180	Protective Role of Anakinra Against Transthyretin-Mediated Axonal Loss and Cell Death in a Mouse Model of Familial Amyloidotic Polyneuropathy. Journal of Neuropathology and Experimental Neurology, 2015, 74, 203-217.	1.7	10

#	Article	IF	Citations
181	Neuronal megalin mediates synaptic plasticityâ€"a novel mechanism underlying intellectual disabilities in megalin gene pathologies. Brain Communications, 2020, 2, fcaa135.	3.3	10
182	Targeting a rare amyloidotic disease through rationally designed polymer conjugates. Journal of Controlled Release, 2014, 178, 95-100.	9.9	9
183	Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 249-253.	3.0	9
184	Transthyretin: No association between serum levels or gene variants and schizophrenia. Journal of Psychiatric Research, 2007, 41, 667-672.	3.1	8
185	Overexpression of Protocadherin-10 in Transthyretin-Related Familial Amyloidotic Polyneuropathy. American Journal of Pathology, 2016, 186, 1913-1924.	3.8	8
186	Transthyretin expression in the postischemic brain. PLoS ONE, 2019, 14, e0221555.	2.5	8
187	Cellular consequences of transthyretin deposition. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10 Suppl 1, 13-6.	3.0	8
188	Evidence for synergistic action of transthyretin and IGF-I over the IGF-I receptor. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 797-804.	3.8	7
189	Force spectroscopy reveals the presence of structurally modified dimers in transthyretin amyloid annular oligomers. Journal of Molecular Recognition, 2017, 30, e2587.	2.1	7
190	SERPINA1 modulates expression of amyloidogenic transthyretin. Experimental Cell Research, 2020, 395, 112217.	2.6	7
191	In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis. International Journal of Molecular Sciences, 2021, 22, 9488.	4.1	7
192	First Spanish family with familial amyloidotic polyneuropathy associated to TTR Thr49Ile mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 34-35.	3.0	6
193	The heat shock response in FAP: the role of the extracellular chaperone clusterin. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 3-4.	3.0	6
194	Familial amyloid polyneuropathy in a Spanish family with a transthyretin deletion (Î"Val 122) presenting with carpal tunnel syndrome. Clinical Genetics, 2000, 58, 411-412.	2.0	5
195	Human transthyretin intronic open reading frames are not independently expressed in vivo or part of functional transcripts. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2003, 1626, 65-74.	2.4	5
196	Familial amyloid polyneuropathy associated with TTRSer50Arg mutation in two Iberian families presenting a novel single base change in the mutant gene. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 147-152.	3.0	5
197	Amyloidogenic properties of transthyretinâ€like protein (TLP) from Escherichia coli. FEBS Letters, 2008, 582, 2893-2898.	2.8	5
198	Tissue remodeling after interference RNA mediated knockdown of transthyretin in a familial amyloidotic polyneuropathy mouse model. Neurobiology of Aging, 2016, 47, 91-101.	3.1	5

#	Article	IF	Citations
199	Anti-TTR Nanobodies Allow the Identification of TTR Neuritogenic Epitope Associated with TTR-Megalin Neurotrophic Activities. ACS Chemical Neuroscience, 2019, 10, 704-715.	3.5	5
200	Successful Heart and Liver Transplantation in a Swiss Patient With Glu89Lys Transthyretin Amyloidosis. Transplantation, 2011, 91, e40-e42.	1.0	4
201	Homozygosity for the E526V Mutation in Fibrinogen A Alpha-Chain Amyloidosis: The First Report. Case Reports in Nephrology, 2015, 2015, 1-6.	0.4	4
202	Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: does the environment play a role?. Transgenic Research, 2013, 22, 101-116.	2.4	3
203	The Expression of Chemokines Is Downregulated in a Pre-Clinical Model of TTR V30M Amyloidosis. Frontiers in Immunology, 2021, 12, 650269.	4.8	3
204	A New Transthyretin Variant Associated with Familial Amyloidotic Polyneuropathy in an Italian Kindred. , 1991, , 599-602.		3
205	Retrovirus-mediated gene transfer of transthyretin and transthyretin-methionine 30: A potential tool for the study of amyloidogenesis. Neuromuscular Disorders, 1993, 3, 275-282.	0.6	2
206	A new transthyretin variant-ATTR Arg l04 Cys. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 149-151.	3.0	2
207	Hsf-1 affects podocyte markers NPHS1, NPHS2 and WT1 in a transgenic mouse model of TTRVal30Met-related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 164-172.	3.0	2
208	Doxycycline-tauroursodeoxycholic acid treatment: effects in the heart of a transthyretin V30M transgenic mouse model. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 80-80.	3.0	2
209	Targeting transthyretin amyloidosis in the eye with next-generation stabilizers: AT40 displays potent TTR stabilization in the human vitreous. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 73-74.	3.0	2
210	TTR Leu 64 in an FAP kindred identified by PCR-RFLP analysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1994, 1, 184-185.	3.0	1
211	LETTERS TO THE EDITOR. Toxicology and Applied Pharmacology, 1997, 144, 204.	2.8	1
212	Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 38-39.	3.0	1
213	Lead optimization of resilient next-generation transthyretin stabilizers for multiple target-product profiles: approaching the CNS. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 77-78.	3.0	1
214	CIBA Foundation Symposium No. 199 The Nature and Origin of Amyloid Fibrils. Lisbon, Portugal, October 23-26, 1995. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1996, 3, 209-211.	3.0	0
215	Third International Symposium on familial amyloidotic polyneuropathy and other TTR related disorders Lisbon, Portugal, October 27â€“28, 1995. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 212-213.	3.0	0
216	Sulphur K-edge XANES Spectroscopy of Transthyretin Amyloid Fibres. Spectroscopy, 2002, 16, 281-283.	0.8	0

#	Article	IF	Citations
217	Downregulated Cathepsin E expression in bone marrow-derived macrophages from the pre-clinical familial amyloid polyneuropathy model. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 63-64.	3.0	0
218	Inflammation and Apoptotic Pathways in the Peripheral Nervous System Related to Protein Misfolding. , 2007, , 271-280.		0
219	Molecular Pathogenesis Associated with Familial Amyloidotic Polyneuropathy. , 2009, , 191-200.		0
220	Transthyretin Aggregation and Toxicity. , 2012, , 407-432.		0
221	A TTR Acidic Variant DNA Analysis Of Homozygous and Heterozygous Individuals. , 1991, , 607-610.		0
222	The importance of pre-clinical studies in animal models of TTR amyloidosis for the discovery of novel patient disease biomarkers. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 83-84.	3.0	0